Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel + Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer
NCT03652428Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by University of Maryland, Baltimore. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03652428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652428.